Exposure to particulate matter (PM) air pollution is associated with increased respiratory and cardiovascular morbidity and mortality ([@b38-ehp0114-000051], [@b35-ehp0114-000051]; [@b43-ehp0114-000051]). Plausible mechanisms explaining the cardiovascular effects of particle exposure have not been clearly defined ([@b50-ehp0114-000051]). However, recent studies provide evidence that PM exposure is associated with systemic inflammation and changes in vascular function that have been implicated in the pathophysiology of cardiovascular disease, providing clues to possible mechanisms. PM exposure has been associated with increased systolic blood pressure ([@b17-ehp0114-000051]), plasma viscosity ([@b36-ehp0114-000051]), C-reactive protein ([@b37-ehp0114-000051]), fibrinogen ([@b33-ehp0114-000051]), and release of leukocytes from the bone marrow ([@b27-ehp0114-000051]; [@b48-ehp0114-000051]). Increases in ambient concentrations of PM were associated with increased blood leukocyte and platelet counts, as well as fibrinogen ([@b44-ehp0114-000051]). [@b6-ehp0114-000051] found evidence for systemic vasoconstriction in resting human subjects exposed to concentrated ambient air particles and ozone.

Ultrafine particles (UFPs), defined as particles with a diameter \< 100 nm, have been hypothesized as contributors to cardiovascular effects of PM ([@b46-ehp0114-000051]) because, compared with fine particles at similar mass concentrations, they have greater pulmonary deposition efficiency ([@b8-ehp0114-000051]; [@b12-ehp0114-000051]), induce more pulmonary inflammation ([@b25-ehp0114-000051]; [@b30-ehp0114-000051]), have enhanced oxidant capacity ([@b7-ehp0114-000051]; [@b24-ehp0114-000051]), have a higher propensity to penetrate the epithelium and reach interstitial sites ([@b47-ehp0114-000051]), and may even enter the systemic circulation in humans ([@b29-ehp0114-000051]; [@b31-ehp0114-000051]).

Relatively few epidemiologic studies have examined the health effects of UFP exposure because most ambient air monitoring measures particle mass, and there is relatively poor correlation between particle mass (dominated by fine particles) and particle number (dominated by UFPs). However, a recent study in Erfurt, Germany, found associations between ambient UFPs and mortality ([@b55-ehp0114-000051]). In a study of patients with stable coronary artery disease ([@b34-ehp0114-000051]), investigators performed repeated exercise tests concurrent with monitoring of ambient particle mass and number counts. Significant independent effects were found for both fine particles and UFPs on the degree of ST-segment depression on the electrocardiogram during exercise.

Asthma, a disease characterized by airway inflammation, confers an increased risk for PM health effects ([@b2-ehp0114-000051]; [@b26-ehp0114-000051]; [@b49-ehp0114-000051]). There is evidence for activation of lung leukocytes and pulmonary vascular endothelium in subjects with asthma, particularly during exacerbations ([@b32-ehp0114-000051]). Activation of T-lymphocytes with production of "type 2" inflammatory cytokines drives the recruitment and retention of eosinophils in the airway, which contribute to the chronic epithelial injury characteristic of this disease ([@b11-ehp0114-000051]; [@b56-ehp0114-000051]). Treatment with inhaled corticosteroids reduces expression of activation markers CD25 and human leukocyte antigen (HLA)-DR in lung lymphocytes and also reduces HLA-DR expression in blood lymphocytes ([@b57-ehp0114-000051]). In asthma, blood CD4^+^ T cells express increased mRNA for interleukin (IL)-4, IL-5, and granulocyte macrophage colony stimulating factor, and IL-5 mRNA expression correlates with asthma severity and eosinophilia ([@b10-ehp0114-000051]). Allergen challenge in subjects with asthma causes a reduction in blood CD4^+^ T cells ([@b53-ehp0114-000051]) and an increase in airway CD4^+^ cells ([@b52-ehp0114-000051]). UFP exposure may worsen asthma by further shifting lymphocyte responses to the type 2 phenotype, by further activating resident lymphocytes, by increasing the likelihood that lymphocytes will encounter antigen, and/or by increasing penetration of allergen through an injured epithelium.

We have initiated controlled exposure studies with carbon UFPs in humans, as a surrogate for environmental UFPs, demonstrating that UFPs have a high pulmonary deposition efficiency in healthy subjects ([@b12-ehp0114-000051]), which is further increased in subjects with asthma ([@b8-ehp0114-000051]). Exposure to 50 μg/m^3^ carbon UFPs caused a reduction in the pulmonary diffusing capacity for carbon monoxide ([@b41-ehp0114-000051]) associated with reductions in the systemic vascular response to increased flow ([@b40-ehp0114-000051]), without significant effects on symptoms, airway inflammation, lung function, or markers of blood coagulation ([@b42-ehp0114-000051]). We hypothesized that inhalation of UFPs alters vascular function, detectable as alterations in blood leukocyte distribution, activation, and expression of adhesion molecules. We further hypothesized that people with asthma, who have airway and systemic inflammation at baseline as well as enhanced UFP deposition, have enhanced susceptibility to these vascular effects. In this article we present detailed analyses of venous blood leukocytes from subjects participating in four separate studies involving carbon UFP exposure: three protocols with varying exposure concentrations in healthy subjects, and one protocol with asthmatic subjects. Some data in this article have been presented previously in abstract form ([@b15-ehp0114-000051]).

Materials and Methods
=====================

Subjects.
---------

Written, informed consent was obtained from all subjects, and the studies were approved by the Research Subjects Review Board of the University of Rochester. Fifty-six never-smoking subjects 18--40 years of age (40 healthy and 16 with asthma) participated and were paid a stipend. Subjects were not studied within 6 weeks of a respiratory infection. Healthy subjects were required to have normal spirometry, a normal 12-lead electrocardiogram, and no history of chronic respiratory disease.

Inclusion criteria for subjects with asthma have been reported previously ([@b8-ehp0114-000051]). These criteria included a consistent clinical history, and either a significant bronchodilator response or airway hyper-responsiveness to methacholine. The severity was consistent with mild intermittent to moderate persistent asthma ([@b28-ehp0114-000051]). Subjects with forced expiratory volume in 1 sec (FEV~1~) \< 70% of predicted at baseline screening, or with \> 20% reduction in FEV~1~ after the screening exercise, were excluded.

Study design.
-------------

Each study used a crossover design in which each subject was exposed to filtered air and to UFPs, so that each subject served as his or her own control. Within each study, the order of air/UFP exposure was randomized, and the randomization was blocked by order of presentation and sex, so that equal numbers of men and women inhaled air first or UFPs first. Exposures were blinded to both subjects and investigators.

[Table 1](#t1-ehp0114-000051){ref-type="table"} provides details of each study protocol. The first, UPREST, involved 12 (six female) subjects exposed at rest to approximately 10 μg/m^3^ UFPs or filtered air for 2 hr. The second study protocol, UPDOSE, involved 12 subjects (six female) with three 2-hr exposures with exercise for each subject: approximately 10 μg/m^3^ UFPs, approximately 25 μg/m^3^ UFPs, and filtered air. Subjects exercised on a bicycle ergometer for 15 min of each half hour at an intensity adjusted to increase the minute ventilation to approximately 20 L/min/m^2^ body surface area. For safety reasons, the order of exposure was randomized in a restricted fashion, so that each subject received the 10-μg/m^3^ exposure before the 25-μg/m^3^. The third protocol, UP50, involved 16 healthy subjects (eight female) exposed to approximately 50 μg/m^3^ UFPs and air for 2 hr, with intermittent exercise as in the UPDOSE protocol. The final protocol, UPASTHMA, involved 16 subjects with asthma (eight female) exposed to approximately 10 μg/m^3^ UFPs and air for 2 hr, with intermittent exercise as in the UPDOSE protocol. All exposures were separated by at least 2 weeks.

Exposures to either filtered air or UFPs were administered by mouthpiece (with nose clip) for 2 hr, interrupted by a 10-min break after the first hour. Before and at 0, 3.5, and 21 hr after exposure, blood pressure, heart rate, and oxygen saturation by pulse oximetry were measured, and blood was drawn from an antecubital vein. For UP50 and UPASTHMA, measurements were also obtained 45 hr after exposure.

Exposure system.
----------------

The rationale and design of the exposure facility have been described in detail elsewhere ([@b9-ehp0114-000051]). Briefly, particles \[count median diameter \~ 25 nm, geometric standard deviation \~ 1.6\] were generated in an argon atmosphere using an electric spark discharge between two graphite electrodes, and then deionized and diluted with filtered air to the desired concentration. Particle number, mass, and size distribution were monitored on both the inspiratory and expiratory sides of the subject. Electronic integration of a pneumotachograph signal provided tidal volume, respiratory frequency, and minute ventilation measurements. Air for the control exposures, and for dilution of the particles, was passed through charcoal and high-efficiency particle filters and was essentially free of particles (0--10 particles/cm^3^).

Blood leukocyte immunofluorescence analysis.
--------------------------------------------

Fresh heparinized whole blood was stained with three monoclonal antibodies: the marker of interest ([Table 2](#t2-ehp0114-000051){ref-type="table"}) conjugated to fluorescein isothiocyanate, CD14 conjugated to phycoerythrin, and CD45 conjugated to pericidin chlorophyll protein. This permitted determination of the relative expression of adhesion molecules and other markers separately on polymorphonuclear leukocytes (PMNs), eosinophils, lymphocytes, and monocytes. The appropriate isotype control antibodies were run with each experiment to assist in appropriate gate setting. The adhesion markers shown in [Table 2](#t2-ehp0114-000051){ref-type="table"} were measured in each of the study protocols, except for CD18, which was measured in UP50 and UPASTHMA only.

Red blood cells were lysed and cells were analyzed on a FACScan flow cytometer (BD Bioscience, San Jose, CA) equipped with a 15-mW argon ion laser emitting at 488 nm. Ten thousand events were collected from each sample in list mode. Standardized fluorescent microbeads (Quantium 24P and 25P; Bangs Laboratories, Fishers, IN) were run with each experiment to convert mean channel numbers to molecules of equivalent soluble fluorochrome (MESF) ([@b16-ehp0114-000051]). This provided a correction for minor day-to-day instrument variations in fluorescence detection.

Total and differential blood leukocyte and platelet counts were performed in the clinical laboratories of Strong Memorial Hospital, using an automated analyzer (Celldyne 4000; Abott Laboratories, Santa Clara, CA).

Data handling and statistical methods.
--------------------------------------

Data were entered on a desktop computer using Microsoft Excel and analyzed using SAS (SAS Institute Inc., Cary, NC).

UPREST, UPASTHMA, and UP50 used a standard, two-period crossover design in which each subject received both particles and air. Equal numbers of males and females were included. The order of presentation was randomized separately for each sex, with half of each group of subjects receiving each of the two possible orders. UPDOSE used a three-period crossover design in which each subject received air and both 10-μg/m^3^ and 25-μg/m^3^ concentrations of particles. There were then three possible exposure sequences, depending on where in the sequence the air exposure was placed. Equal numbers of subjects were randomly assigned to each sequence.

Repeated-measures analysis of variance (ANOVA) was used ([@b54-ehp0114-000051]), with order of presentation as a between-subjects factor, with exposure and time as within-subject factors. The analysis included tests for period and carryover effects, although the latter were expected to be minimal because of the nature of the exposures and the length of the washout period. In cases where carryover effects were significant, first-period data were examined separately ([@b18-ehp0114-000051]). Each ANOVA included an examination of residuals as a check on the required assumptions of normally distributed errors with constant variance. If these assumptions were not satisfied, data transformations (e.g., square-root transformation for cell counts) were considered. A *p*-value of 0.05 was required for statistical significance. Data are shown as mean ± SE, unless otherwise indicated.

Results
=======

Exposure data and subject characteristics.
------------------------------------------

[Table 3](#t3-ehp0114-000051){ref-type="table"} shows the exposure parameters and subject characteristics for each protocol. Most of the subjects with asthma were atopic (15 of 16), and most (11 of 16) were not on inhaled steroids, long-acting bronchodilators, or leukotriene inhibitors. All subjects completed every exposure; men and women did not differ in the achieved minute ventilation, adjusted for body surface area. There were no significant effects of UFP exposure on ventilatory parameters or pulmonary function; these results, and UFP deposition, have been published previously ([@b12-ehp0114-000051]).

The UPREST protocol, with exposures at rest to 10 μg/m^3^ UFPs, showed no convincing differences between particle and air exposure for leukocyte expression of adhesion molecules or total and differential leukocyte counts. There were rare statistically significant comparisons, but the significance levels were modest, and the data did not suggest a consistent biologic response. Overall, exposure to 10 μg/m^3^ UFPs at rest had no significant effects on blood leukocytes.

Findings from the three studies involving exercise are described below.

Blood leukocyte expression of adhesion molecules.
-------------------------------------------------

In these studies, quantitative surface expression of molecules that mediate leukocyte-endothelial interactions served as an indirect indicator of exposure effects on pulmonary vascular endothelial function. The use of flow cytometry with calibrated fluorescent beads allowed quantitation of small changes in surface marker density. Adhesion molecule expression for monocytes and PMNs in the three protocols involving exercise is shown in [Tables 4](#t4-ehp0114-000051){ref-type="table"}--[6](#t6-ehp0114-000051){ref-type="table"}.

UPDOSE.
-------

UFP exposure caused a concentration-related reduction in monocyte expression of CD54 \[intercellular adhesion molecule-1 (ICAM-1) (exposure effect, *p* = 0.0012); [Figure 1](#f1-ehp0114-000051){ref-type="fig"}\]. Expression increased after exposure to filtered air and decreased with 25 μg/m^3^ UFPs, with differences resolving by 21 hr after exposure. Expression of CD62L showed a significant exposure--sex interaction (*p* = 0.0006; data not shown), with expression increasing in females but decreasing in males relative to air exposure. However, these findings lacked a clear concentration response.

UP50.
-----

Exposure to 50 μg/m^3^ UFPs also reduced expression of CD54 on monocytes ([Figure 2A,B](#f2-ehp0114-000051){ref-type="fig"}), but to a greater extent in males (exposure--sex interaction, *p* = 0.025). The percentage of monocytes expressing CD54 was also reduced (*p* = 0.035; data not shown). UFP exposure persistently blunted the air-related increase in CD18 expression on monocytes (*p* = 0.0002; [Figure 2C](#f2-ehp0114-000051){ref-type="fig"}). Expression of CD18 was also reduced on PMNs ([Figure 2D](#f2-ehp0114-000051){ref-type="fig"}), and ANOVA indicated significantly increased CD11a expression on PMNs (exposure--time interaction, *p* = 0.037; data not shown).

UPASTHMA.
---------

As expected, we found baseline differences between healthy and asthmatic subjects in leukocyte expression of adhesion molecules; these data are shown in [Table 7](#t7-ehp0114-000051){ref-type="table"}. For example, monocyte expression of CD11b, CD54, and CD62L was higher in subjects with asthma than in healthy subjects.

In subjects with asthma, exposure to 10 μg/m^3^ UFPs reduced expression of CD11b on blood monocytes (*p* = 0.029; [Figure 3A](#f3-ehp0114-000051){ref-type="fig"}) and also reduced expression on eosinophils (*p* = 0.015; [Figure 3B](#f3-ehp0114-000051){ref-type="fig"}). Expression of CD62L on PMNs increased in males but not females (exposure--sex interaction, *p* = 0.011; [Figure 3C,D](#f3-ehp0114-000051){ref-type="fig"}). Expression of CD54 on PMNs decreased, with the greatest difference from control at 45 hr after exposure (exposure--time interaction, *p* = 0.031; data not shown).

Lymphocyte subsets and activation.
----------------------------------

There was evidence for increased activated T cells after UFP exposure in healthy subjects. In UPDOSE, CD25 expression on CD3^+^ T cells increased in females, but not in males, early after exposure to 25 μg/m^3^ UFPs (exposure--sex interaction, *p* = 0.002; [Figure 4A,B](#f4-ehp0114-000051){ref-type="fig"}). In UP50, exposure to 50 μg/m^3^ increased CD25 expression on T cells 0 hr after exposure (*p* = 0.001 by paired *t*-test at 0 hr after exposure; *p* = 0.085 by ANOVA; [Figure 4C](#f4-ehp0114-000051){ref-type="fig"}). There were no other changes in lymphocyte subsets in the healthy subjects.

In UPASTHMA, CD4^+^ T cells decreased immediately after exposure to UFPs, compared with air (exposure--time interaction, *p* = 0.021; [Figure 2D](#f2-ehp0114-000051){ref-type="fig"}). There were no significant effects on other lymphocyte subsets or CD25 expression. However, the percentage of T-lymphocytes expressing the activation marker CD25 was higher in asthmatic subjects than in healthy subjects before exposure (UPASTHMA, 33.0 ± 3.3%, vs. UPDOSE, 27.0 ± 2.5%; *p* = 0.04).

Overall, the data suggest that UFP exposure induces activation (healthy subjects) or sequestration (subjects with asthma) of T-lymphocytes.

Blood leukocyte and platelet counts.
------------------------------------

In each of the protocols involving exercise (UPDOSE, UP50, and UPASTHMA), consistent postexposure increases were seen in the total leukocyte count and the percentage of PMNs, with decreases in the percentage of eosinophils and monocytes. In the UPDOSE protocol, ANOVA showed a significant exposure--sex interaction for an effect on the percentage of blood monocytes (*p* = 0.0015). As shown in [Figure 5A,B](#f5-ehp0114-000051){ref-type="fig"}, in females monocytes decreased after exposure to 25 μg/m^3^ and did not return to baseline at 21 hr after exposure. This observation was confirmed when monocyte numbers were analyzed by flow cytometry, using light scatter and CD14 expression (overall effect of UFPs, *p* = 0.035; exposure--sex interaction, *p* = 0.002). A significant decrease in blood basophils in females was also seen with both UFP concentrations (exposure--sex interaction, *p* = 0.015; data not shown).

Exposure to 50 μg/m^3^ UFPs caused small reductions in the percentage of eosinophils, with a larger effect in females ([Figure 5C,D](#f5-ehp0114-000051){ref-type="fig"}). There were no significant effects on the percentage of blood monocytes, PMNs, or basophils in this protocol.

In subjects with asthma exposed to 10 μg/m^3^ UFPs, basophils decreased in both men and women at 0 and 3.5 hr after exposure to UFPs, compared with air exposure (exposure--time interaction, *p* = 0.02; data not shown). The percentage of blood eosinophils as determined by flow cytometry decreased 0 and 3.5 hr after exposure, with greater reductions after UFP exposure than after air (*p* = 0.049).

UFP exposure did not change platelet counts in any of the exposure protocols.

These data suggest that exposure to UFPs with exercise causes small changes in blood leukocyte differential counts in both healthy and asthmatic subjects.

Discussion
==========

The objective of these studies was to determine whether inhalation of carbon UFPs has vascular effects in healthy subjects, and in subjects with asthma. We postulated that changes in blood leukocyte phenotype and expression of adhesion molecules would serve as a "window" on vascular inflammatory effects after inhalation challenge. Although the specific findings differed among the protocols, all three protocols with exercise showed UFP-associated reductions in expression of adhesion molecules on leukocytes, mainly ICAM-1 (CD54) and the β~2~ integrins CD11b and CD18. There were significant differences between healthy and asthmatic subjects in leukocyte expression of adhesion molecules, when measured before exposure ([Table 7](#t7-ehp0114-000051){ref-type="table"}). For example, blood monocytes from subjects with asthma showed decreased expression of CD11a and increased expression of CD11b, CD49d, and CD54 relative to healthy subjects. This may reflect relative activation or priming of circulating leukocytes as a consequence of airway inflammation. In subjects with asthma, inhalation of UFPs reduced expression of CD11b on monocytes and eosinophils ([Figure 3](#f3-ehp0114-000051){ref-type="fig"}) and reduced CD54 expression on PMNs ([Table 6](#t6-ehp0114-000051){ref-type="table"}).

In addition, the data suggested subtle reductions relative to air exposure in the percentage of blood monocytes, eosinophils, and basophils. There was evidence for activation of CD4^+^ T-lymphocytes in healthy subjects and transient reductions in CD4^+^ T-cell numbers in asthmatic subjects. Sex interactions were seen for some of these changes. A summary of these findings is shown in [Table 8](#t8-ehp0114-000051){ref-type="table"}.

The findings provide evidence that inhalation of elemental carbon UFPs, with intermittent exercise, causes phenotypic alterations in blood leukocytes at concentrations as low as approximately 10 μg/m^3^ or approximately 2 × 10^6^ particles/cm^3^. However, the overall nature and direction of the changes do not suggest increased systemic inflammation. This is consistent with the lack of evidence for airway or systemic inflammation that we have reported previously for these studies ([@b40-ehp0114-000051], [@b42-ehp0114-000051]).

The reductions in leukocyte subsets and adhesion molecule expression seen in these studies suggest the possibility of leukocyte sequestration or margination in response to UFP exposure. The relative reductions in monocyte, basophil, and eosinophil percentages may result from slightly prolonged transit time through the pulmonary circulation after exposure to UFPs, possibly as a consequence of pulmonary vasoconstriction. The reductions in expression of the adhesion molecules CD54, CD11b, and CD18 are consistent with this hypothesis. Blood leukocytes normally marginate in the lung, requiring several seconds to transit the pulmonary circulation ([@b14-ehp0114-000051]). PMNs are larger than pulmonary capillaries and must deform in order to transit. The integrins CD11a and CD11b are expressed as dimers with CD18 and mediate blood leukocyte recruitment to areas of inflammation and injury via specific receptors on vascular endothelial cells. Activation of monocytes and PMNs increases expression of CD11b and CD18 and decreases cell deformability through actin polymerization ([@b1-ehp0114-000051]), slowing transit time. Exercise increases pulmonary blood flow and decreases leukocyte transit time through the pulmonary circulation, leading to mobilization of the pulmonary leukocyte pool into the systemic vascular pool. [@b51-ehp0114-000051] have shown that maximal exercise increases the blood leukocyte count and also increases expression of CD11b on peripheral blood PMNs, suggesting that cells expressing higher levels of CD11b preferentially marginate in the pulmonary circulation and are "flushed out" with exercise. Thus, our data are consistent with, but do not prove, increased retention of leukocytes expressing higher levels of adhesion molecules in the pulmonary vascular bed in response to UFP exposure.

Pulmonary vasoconstriction in response to UFP exposure would be expected to delay leukocyte transit through the lung. We have reported ([@b41-ehp0114-000051]) that, in the UP50 protocol, UFP exposure caused reductions in the diffusing capacity for carbon monoxide, without effects on the forced vital capacity, consistent with reduced vascular perfusion or reduced ventilation/perfusion matching. We also reported preliminary findings ([@b40-ehp0114-000051]) of subtle but significant effects on systemic flow-mediated vascular dilatation, and a decrease in blood nitrate levels, suggesting the vascular effects may result from decreased nitric oxide availability. [@b3-ehp0114-000051] have shown pulmonary vaso-constriction in rats exposed to concentrated ambient fine particles.

Alternative mechanisms for reductions in leukocyte and their surface markers include *a*) direct effects of UFPs on blood leukocytes, reducing surface marker expression through shedding, redistribution, or internalization; *b*) indirect effects of mediators released by vascular endothelium, such as nitric oxide, which has anti-inflammatory properties ([@b22-ehp0114-000051]), reduces endothelial expression of adhesion molecules via inhibition of nuclear factor κB activation, and reduces monocyte adhesion to endothelium ([@b13-ehp0114-000051]); *c*) adsorption of soluble cytokines, such as transforming growth factor-β, onto the surface of the particles, reducing inflammatory effects ([@b19-ehp0114-000051]); *d*) recruitment of immature leukocytes from the bone marrow in response to UFP inhalation, as has been suggested in previous studies of fine particle exposure ([@b48-ehp0114-000051]); and *e*) selective toxicity of UFPs for activated blood leukocytes, inducing apoptosis of specific cell subsets.

The two protocols with exercise in healthy subjects showed increased expression of CD25 on blood T-lymphocytes, and subjects with asthma showed a transient reduction in CD4^+^ lymphocytes after UFP exposure. CD25 is the α-chain of the IL-2 receptor; IL-2 promotes lymphocyte proliferation. We found that lymphocyte CD25 expression was higher in subjects with asthma than in healthy subjects, confirming previous observations that people with asthma have a higher percentage of circulating activated T-lymphocytes ([@b11-ehp0114-000051]), which may explain why UFP exposure did not increase it further in these subjects. The rapid and transient nature of the reduction in CD4^+^ T cells suggests redistribution or margination of cells, as postulated above for other blood leukocytes.

The changes in response to carbon UFP exposure reported in these studies were generally small and would not be expected to adversely affect healthy and mildly asthmatic subjects similar to those studied. However, ambient UFPs contain reactive organic species and transition metals that may induce greater effects than those we observed. People with severely compromised cardiovascular status may experience adverse effects from even small changes in vascular homeostasis. Furthermore, prolonged, repeated exposures may hasten the progression of atherosclerosis, as has been suggested in an epidemiology study of fine particle exposure ([@b21-ehp0114-000051]).

The UFP number concentrations used in these studies are higher than UFP background concentrations but are relevant to episodic levels seen in specific situations. UFPs are always present in ambient air, with background urban levels in the range of 40,000--50,000 particles/cm^3^ or estimated mass concentrations of 3--4 μg/m^3^ ([@b39-ehp0114-000051]). Episodic increases have been documented to 300,000 particles/cm^3^, or estimated to approximately 50 μg/m^3^ UFPs as an hourly average ([@b4-ehp0114-000051], [@b5-ehp0114-000051]). Particle numbers inside a vehicle on a major highway reached 10^7^ particles/cm^3^ ([@b20-ehp0114-000051]), comparable with the highest concentrations used in our studies.

Although not specifically powered to detect sex differences, these studies were designed to include an analysis of sex interactions with the effects of UFP exposure. In the UPDOSE protocol, females showed greater decreases in blood monocytes ([Figure 5A](#f5-ehp0114-000051){ref-type="fig"}) and basophils and greater increases lymphocyte CD25 expression ([Figure 4A](#f4-ehp0114-000051){ref-type="fig"}) compared with males. Females also showed decreased eosinophils in the UP50 protocol ([Figure 5C](#f5-ehp0114-000051){ref-type="fig"}). In UPASTHMA, expression of L-selectin (CD62L) on PMNs was increased in males ([Figure 3B](#f3-ehp0114-000051){ref-type="fig"}). It is possible that males and females differ in their cardiovascular responses to particle exposure. There are known sex differences in leukocyte function and cardiovascular responses, based in part on hormonal influences. For example, females have a higher percentage of CD4^+^ T cells and a higher CD4^+^:CD8^+^ ratio than do males. Stimulated blood monocytes from females produce more prostaglandin E~2~ ([@b23-ehp0114-000051]) and less tumor necrosis factor-α and IL-6 ([@b45-ehp0114-000051]) than those from males. There are also sex differences in endothelial function and antioxidant defenses that may affect vascular response to inhaled challenge. However, we do not feel that these studies have convincingly established or excluded significant sex differences in responses to carbon UFPs.

There are limitations to this study. First, our particles were laboratory-generated elemental carbon, without significant organic species, metals, oxides, nitrates, or sulfates. The findings of these studies may not be representative of exposure to ambient particles, which are a mix of ultrafine, fine, and coarse particles, with reactive organic species, metals, and oxidants in addition to elemental carbon. These and other chemical species may enhance pulmonary and vascular effects. Second, each protocol involved a fairly large number of measurements, and some statistically significant changes may have been chance related. Our approach was to consider results that showed consistency within and across protocols and to discount findings of isolated statistical significance that were not supported by other data. The observations of UFP effects on leukocyte distribution and surface marker expression meet those criteria.

Conclusions
===========

Overall, the findings from these studies provide evidence that inhalation of carbon UFPs, with exercise, reduces peripheral blood monocytes, eosinophils, and basophils and reduces expression of some adhesion molecules on monocytes and PMNs. When considered in light of other evidence, the leukocyte changes may be a consequence of endothelial activation or vasoconstriction in the pulmonary and/or systemic circulation.
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![Changes in monocyte expression of CD54 (ICAM-1), UPDOSE protocol. In this and following figures, data are shown as mean ± SE changes from baseline. Nominal UFP exposure concentrations are shown in μg/m^3^. Exposure, *p* = 0.012.](ehp0114-000051f1){#f1-ehp0114-000051}

![Changes in leukocyte expression of adhesion molecules, UP50 protocol. (*A*) Monocyte expression of CD54, females. UFP × sex, *p* = 0.025. (*B*) Monocyte expression of CD54, males. UFP × sex, *p* = 0.025. (*C*) Monocyte expression of CD18. UFP, *p* = 0.0002. (*D*) PMN expression of CD18. UFP, *p* = 0.023.](ehp0114-000051f2){#f2-ehp0114-000051}

![Changes in leukocyte expression of adhesion molecules, UPASTHMA protocol. (*A*) Monocyte expression of CD11b. UFP, *p* = 0.029. (*B*) Eosinophil expression of CD11b. UFP, *p* = 0.015. (*C*) PMN expression of CD62L, females. UFP × sex, *p* = 0.011. (*D*) PMN expression of CD62L, males. UFP × sex, *p* = 0.011.](ehp0114-000051f3){#f3-ehp0114-000051}

![Changes in blood T-lymphocyte subsets. (*A*) UPDOSE protocol, percentage of CD25^+^ cells within the T-cell (CD3^+^) gate, females. UFP × sex, *p* = 0.0024. (*B*) UPDOSE protocol, CD3^+^CD25^+^ T cells, males. UFP × sex, *p* = 0.0024. (*C*) UP50 protocol, CD3^+^CD25^+^ T cells, all subjects. UFP × time, *p* = 0.085. (*D*) UPASTHMA protocol, CD4^+^ T cells, all subjects. UFP × time, *p* = 0.021.](ehp0114-000051f4){#f4-ehp0114-000051}

![Changes in percentage of blood leukocytes with exposure to UFPs. (*A*) UPDOSE protocol, monocytes, females. UFP × sex, *p* = 0.0015. (*B*) UPDOSE protocol, monocytes, males. UFP × sex, *p* = 0.0015. (*C*) UP50 protocol, eosinophils, females. UFP × time × sex, *p* = 0.01. (*D*) UP50 protocol, eosinophils, males. UFP × time × sex, *p* = 0.01.](ehp0114-000051f5){#f5-ehp0114-000051}

###### 

Study design (mean ± SD).

                                                                                  UPREST        UPDOSE                  UP50                    UPASTHMA
  ------------------------------------------------------------------------------- ------------- ----------------------- ----------------------- -----------------------
  No. of subjects                                                                 12            12                      16                      16
  Subject age (years)                                                             30.1 ± 8.9    26.9 ± 5.8              26.9 ± 6.5              23.0 ± 2.7
  FEV~1~ (% predicted)                                                            103.8 ± 8.0   106.3 ± 16.6            102.8 ± 9.5             97.6 ± 5.0
  Nominal[a](#tfn1-ehp0114-000051){ref-type="table-fn"} particle mass (μg/m^3^)   0, 10         0, 10, 25               0, 50                   0, 10
  Rest/exercise                                                                   Rest          Intermittent exercise   Intermittent exercise   Intermittent exercise

The target mass concentration of UFPs for each protocol.

###### 

Leukocyte markers measured in each protocol.

  Cluster designation                                  Name                                Source (clone)                                                                                                                 Description
  ---------------------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------
  CD3                                                                                      BD Bioscience[a](#tfn2-ehp0114-000051){ref-type="table-fn"} (SK7)                                                              Marker of T-lymphocytes
  CD4                                                                                      BD Bioscience (SK3)                                                                                                            Marker of T-helper lymphocytes
  CD8                                                                                      BD Bioscience (SK1)                                                                                                            Marker of T-cytotoxic lymphocytes
  CD11a                                                Leukocyte function antigen-1        GenTrak[b](#tfn3-ehp0114-000051){ref-type="table-fn"} (38) or Coulter[c](#tfn4-ehp0114-000051){ref-type="table-fn"} (25.3.1)   Part of β~2~ integrin adhesion molecule complex
  CD11b                                                Mac-1                               Ancell[d](#tfn5-ehp0114-000051){ref-type="table-fn"} (ICRF44)                                                                  Subunit of complement receptor 3, part of β2 integrin adhesion molecule complex
  CD18[e](#tfn6-ehp0114-000051){ref-type="table-fn"}                                       Pharmigen[a](#tfn2-ehp0114-000051){ref-type="table-fn"} (6.7) or BD Bioscience (L130)                                          Part of β~2~ adhesion molecule complex with CD11a and CD11b
  CD25                                                 Tac                                 BD Bioscience (2A3)                                                                                                            Epitope of IL-2 receptor, activation marker on lymphocytes
  CD49d                                                Very late antigen-α4                Serotec[f](#tfn7-ehp0114-000051){ref-type="table-fn"} (44H6)                                                                   Part of β~1~ integrin adhesion molecule complex
  CD54                                                 Intercellular adhesion molecule-1   Southern Biotechnology[g](#tfn8-ehp0114-000051){ref-type="table-fn"} (15.2)                                                    Adhesion molecule
  CD62L                                                L-selectin                          Coulter (DREG56) or Pharmigen (DREG56)                                                                                         Adhesion molecule

San Jose, CA.

Plymouth Meeting, PA.

Miami, FL.

Bayport, MN.

Measured in UP50 and UPASTHMA only.

Raleigh, NC.

Birmingham, AL.

###### 

Exposure parameters (mean ± SD).

                                              UPREST         UPDOSE         UPDOSE         UP50           UPASTHMA
  ------------------------------------------- -------------- -------------- -------------- -------------- --------------
  Nominal particle mass (μg/m^3^)             10             10             25             50             10
  Measured particle mass (μg/m^3^)            10.00 ± 2.14   13.87 ± 4.02   28.46 ± 5.13   49.97 ± 3.88   11.08 ± 3.11
  Particle number (× 10^6^ particles/cm^3^)   1.88 ± 0.09    2.04 ± 0.07    6.96 ± 0.10    10.79 ± 1.66   2.20 ± 0.10
  CMD (nm)                                    27.3 ± 2.5     25.2 ± 1.7     26.5 ± 1.5     27.9 ± 2.2     23.1 ± 1.6
  GSD                                         1.62 ± 0.02    1.60 ± 0.02    1.60 ± 0.02    1.65 ± 0.02    1.64 ± 0.01

Abbreviations: CMD, count median diameter; GSD, geometric standard deviation.

###### 

Adhesion molecule expression on monocytes and PMNs, UPDOSE protocol (mean ± SE, MESF).

              Exposure (μg/m^3^)   Baseline         0 hr             3.5 hr           21 hr            ANOVA
  ----------- -------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Monocytes                                                                                            
   CD11a      Air                  64,429 ± 2,072   62,483 ± 2,140   62,571 ± 1,689   65,682 ± 2,435   
              UFP 10               63,818 ± 4,109   59,900 ± 2,493   59,190 ± 3,063   65,249 ± 2,518   
              UFP 25               62,835 ± 2,644   56,207 ± 5,436   59,635 ± 2,404   63,008 ± 2,126   
   CD11b      Air                  19,034 ± 986     19,497 ± 997     21,076 ± 1,653   20,901 ± 1,912   
              UFP 10               17,632 ± 990     17,287 ± 1,171   18,335 ± 1,501   19,391 ± 1,185   
              UFP 25               19,056 ± 1,214   17,769 ± 922     22,059 ± 4,697   22,669 ± 3,357   
   CD49d      Air                  14,222 ± 1,000   13,562 ± 854     13,717 ± 880     13,989 ± 964     
              UFP 10               13,634 ± 1,029   12,587 ± 694     12,946 ± 706     13,059 ± 797     
              UFP 25               13,590 ± 839     12,779 ± 574     12,372 ± 683     13,542 ± 935     
   CD54       Air                  12,188 ± 319     13,096 ± 519     13,908 ± 645     13,307 ± 823     Exposure
              UFP 10               12,541 ± 469     12,470 ± 583     12,855 ± 592     13,110 ± 781     *p* = 0.001
              UFP 25               13,717 ± 686     12,591 ± 584     13,533 ± 856     14,482 ± 991     
   CD62L      Air                  43,970 ± 3,212   34,937 ± 3,519   37,600 ± 3,391   37,399 ± 3,716   Exposure × sex
              UFP 10               38,953 ± 3,465   30,281 ± 2,510   32,409 ± 1,719   36,356 ± 3,207   *p* = 0.006
              UFP 25               41,357 ± 4,453   33,134 ± 2,940   34,676 ± 3,234   39,168 ± 4,196   
  PMNs                                                                                                 
   CD11a      Air                  28,637 ± 1,073   28,613 ± 1,228   28,793 ± 1,183   28,867 ± 1,503   
              UFP 10               29,124 ± 1,073   26,216 ± 1,160   26,260 ± 985     27,620 ± 923     
              UFP 25               28,444 ± 1,397   27,939 ± 1,151   27,817 ± 1,137   27,157 ± 1,411   
   CD11b      Air                  18,467 ± 1,117   18,837 ± 1,223   21,427 ± 3,186   21,189 ± 2,383   
              UFP 10               16,728 ± 907     15,997 ± 1,175   16,049 ± 1,112   21,169 ± 2,394   
              UFP 25               19,778 ± 2,671   15,671 ± 1,179   20,461 ± 3,457   18,653 ± 1,760   
   CD49d      Air                  7,422 ± 593      6,572 ± 542      6,404 ± 498      6,098 ± 686      Exposure × sex
              UFP 10               7,007 ± 561      6,172 ± 559      6,173 ± 423      6,340 ± 650      *p* = 0.007
              UFP 25               6,681 ± 465      6,031 ± 442      5,677 ± 446      5,925 ± 470      
   CD54       Air                  4,792 ± 279      4,500 ± 280      4,586 ± 246      4,457 ± 243      
              UFP 10               4,953 ± 271      4,292 ± 242      4,608 ± 424      4,435 ± 213      
              UFP 25               4,771 ± 321      4,084 ± 216      4,122 ± 215      4,417 ± 230      
   CD62L      Air                  66,179 ± 3,910   59,419 ± 4,413   64,867 ± 4,303   59,671 ± 5,970   
              UFP 10               60,976 ± 4,340   57,202 ± 4,515   56,621 ± 4,636   60,626 ± 4,180   
              UFP 25               66,145 ± 4,231   60,044 ± 5,434   59,625 ± 4,296   61,184 ± 4,054   

###### 

Adhesion molecule expression on monocytes and PMNs, UP50 protocol (mean ± SE, MESF).

              Exposure   Baseline         0 hr             3.5 hr           21 hr            45 hr            ANOVA
  ----------- ---------- ---------------- ---------------- ---------------- ---------------- ---------------- -----------------
  Monocytes                                                                                                   
   CD11a      Air        65,882 ± 3,277   66,463 ± 2,934   65,658 ± 2,963   69,888 ± 2,853   71,292 ± 2,885   
              UFP        69,090 ± 3,146   68,680 ± 2,935   66,222 ± 2,696   69,813 ± 2,835   71,773 ± 3,132   
   CD11b      Air        16,840 ± 899     20,104 ± 905     19,938 ± 835     18,728 ± 1,092   18,364 ± 993     
              UFP        18,365 ± 1,153   19,733 ± 1,206   18,531 ± 952     18,389 ± 932     18,369 ± 815     
   CD18       Air        62,675 ± 2,948   68,897 ± 2,942   67,872 ± 2,780   68,661 ± 2,749   68,963 ± 3,187   Exposure
              UFP        67,246 ± 2,751   67,175 ± 2,582   66,277 ± 2,488   67,307 ± 2,768   68,754 ± 3,052   *p* = 0.0002
   CD49d      Air        16,334 ± 939     16,588 ± 859     17,371 ± 954     16,951 ± 9,571   17,126 ± 1,079   
              UFP        16,643 ± 938     16,445 ± 874     17,182 ± 965     17,282 ± 909     17,484 ± 1,167   
   CD54       Air        9,637 ± 1,431    10,654 ± 1,668   11,198 ± 1,728   9,969 ± 1,639    9,827 ± 1,687    Exposure × sex
              UFP        10,526 ± 1,715   11,095 ± 1,782   10,889 ± 1,871   10,352 ± 1,791   10,339 ± 1,811   *p* = 0.025
   CD62L      Air        58,551 ± 3,188   50,197 ± 3,410   48,580 ± 3,027   9,699 ± 1,557    59,189 ± 2,271   
              UFP        57,666 ± 3,519   49,307 ± 3,261   50,241 ± 2,848   56,880 ± 3,515   58,283 ± 3,020   
  PMNs                                                                                                        
   CD11a      Air        30,921 ± 851     30,934 ± 862     31,339 ± 960     31,683 ± 944     31,712 ± 937     Exposure × time
              UFP        31,569 ± 1,014   32,158 ± 1,055   31,652 ± 912     31,751 ± 927     32,130 ± 921     *p* = 0.037
   CD11b      Air        16,406 ± 628     18,053 ± 934     17,262 ± 678     17,355 ± 869     17,525 ± 848     
              UFP        16,678 ± 830     19,155 ± 1,953   17,076 ± 777     18,014 ± 713     17,545 ± 694     
   CD18       Air        34,919 ± 1,335   36,961 ± 1,352   36,486 ± 1,286   35,907 ± 1,226   35,868 ± 1,450   Exposure
              UFP        36,010 ± 1,032   37,687 ± 1,810   36,255 ± 1,060   35,316 ± 983     35,682 ± 1,087   *p* = 0.023
   CD49d      Air        6,455 ± 412      6,345 ± 264      6,399 ± 279      6,145 ± 204      6,070 ± 203      
              UFP        6,186 ± 335      6,252 ± 330      6,362 ± 340      6,284 ± 305      6,114 ± 258      
   CD54       Air        8,182 ± 584      8,339 ± 484      8,973 ± 552      8,114 ± 415      8,072 ± 383      
              UFP        8,524 ± 427      9,071 ± 545      8,668 ± 458      8,501 ± 402      8,446 ± 389      
   CD62L      Air        87,437 ± 4,510   88,596 ± 3,485   88,617 ± 4,056   87,244 ± 3,362   89,489 ± 2,648   
              UFP        92,053 ± 4,760   89,783 ± 4,262   90,736 ± 4,227   89,363 ± 3,898   94,055 ± 4,598   

###### 

Adhesion molecule expression on monocytes and PMNs, UPASTHMA protocol (mean ± SE, MESF).

              Exposure   Baseline         0 hr             3.5 hr           21 hr            45 hr            ANOVA
  ----------- ---------- ---------------- ---------------- ---------------- ---------------- ---------------- -----------------
  Monocytes                                                                                                   
   CD11a      Air        21,179 ± 4,120   20,442 ± 3,989   19,336 ± 4,042   21,126 ± 5,569   21,407 ± 5,550   
              UFP        32,102 ± 7,076   30,277 ± 6,791   29,592 ± 6,630   30,468 ± 6,809   29,751 ± 6,640   
   CD11b      Air        25,022 ± 2,822   31,626 ± 5,969   26,553 ± 3,319   26,345 ± 3,456   27,703 ± 3,228   Exposure
              UFP        26,958 ± 4,112   25,452 ± 4,611   25,742 ± 4,241   24,498 ± 4,199   25,814 ± 3,502   *p* = 0.029
   CD18       Air        85,586 ± 6,773   87,234 ± 8,882   82,899 ± 6,465   82,697 ± 7,370   85,455 ± 7,819   
              UFP        84,999 ± 7,252   81,131 ± 7,931   81,297 ± 9,950   82,028 ± 6,767   77,346 ± 7,334   
   CD49d      Air        17,172 ± 731     16,739 ± 925     16,013 ± 616     16,627 ± 837     16,856 ± 771     
              UFP        18,378 ± 865     16,967 ± 873     17,138 ± 919     17,715 ± 877     17,327 ± 879     
   CD54       Air        19,102 ± 1,386   19,432 ± 1,430   18,285 ± 1,248   19,043 ± 1,410   19,281 ± 1,319   
              UFP        20,673 ± 2,009   20,438 ± 2,088   19,861 ± 1,934   20,014 ± 1,853   19,284 ± 1,491   
   CD62L      Air        45,571 ± 2,571   39,446 ± 2,652   41,214 ± 2,703   45,100 ± 2,847   44,329 ± 2,870   
              UFP        51,939 ± 5,305   43,483 ± 4,955   42,198 ± 3,954   46,105 ± 4,023   45,608 ± 4,271   
  PMNs                                                                                                        
   CD11a      Air        10,540 ± 1,775   10,010 ± 1,771   10,107 ± 1,837   10,986 ± 2,830   11,199 ± 2,953   
              UFP        14,562 ± 2,749   14,161 ± 2,679   13,790 ± 2,780   13,765 ± 2,727   13,710 ± 2,652   
   CD11b      Air        24,078 ± 2,783   26,353 ± 3,578   25,211 ± 2,533   25,199 ± 2,072   30,893 ± 4,350   
              UFP        23,819 ± 2,343   22,792 ± 3,224   25,376 ± 2,984   22,085 ± 2,479   22,781 ± 1,886   
   CD18       Air        48,861 ± 3,054   47,564 ± 3,026   45,449 ± 2,457   45,303 ± 2,719   50,312 ± 5,429   
              UFP        46,982 ± 2,925   44,465 ± 2,676   43,512 ± 3,174   44,599 ± 2,862   43,470 ± 3,006   
   CD49d      Air        5,342 ± 211      5,122 ± 228      5,090 ± 162      4,805 ± 248      4,923 ± 185      
              UFP        5,499 ± 315      4,964 ± 212      4,887 ± 210      4,783 ± 234      4,950 ± 241      
   CD54       Air        5,631 ± 230      5,348 ± 236      5,234 ± 222      5,433 ± 277      5,635 ± 239      Exposure × time
              UFP        6,262 ± 451      5,759 ± 453      5,604 ± 458      5,535 ± 399      5,660 ± 398      *p* = 0.031
   CD62L      Air        78,859 ± 3,812   69,825 ± 3,978   71,796 ± 3,691   72,829 ± 4,711   72,429 ± 4,184   Exposure × sex
              UFP        79,315 ± 6,332   75,646 ± 6,405   70,468 ± 4,961   74,971 ± 5,500   74,541 ± 5,925   *p* = 0.011

###### 

Blood leukocyte marker expression at baseline that differed between asthmatic and healthy subjects (mean ± SE, MESF).

                Healthy[a](#tfn10-ehp0114-000051){ref-type="table-fn"}   Asthma           *p*-Value
  ------------- -------------------------------------------------------- ---------------- -----------
  Lymphocytes                                                                             
   CD11a        41,710 ± 1,844                                           14,575 ± 4,161   \< 0.001
   CD11b        1,460 ± 67                                               1,784 ± 107      0.017
   CD49d        8,168 ± 335                                              10,486 ± 324     \< 0.001
   CD54         2,381 ± 69                                               2,964 ± 155      0.003
  Monocytes                                                                               
   CD11a        64,155 ± 4,041                                           26,220 ± 5,260   \< 0.001
   CD11b        17,944 ± 915                                             25,047 ± 2,751   0.025
   CD49d        13,556 ± 915                                             17,089 ± 642     0.005
   CD54         12,314 ± 401                                             17,942 ± 1,065   \< 0.001
  PMNs                                                                                    
   CD11a        28,358 ± 904                                             12,753 ± 2,276   \< 0.001
   CD11b        16,868 ± 1,055                                           24,178 ± 2,705   0.021
   CD49d        7,189 ± 545                                              5,292 ± 282      0.007
   CD62L        63,591 ± 4,614                                           80,656 ± 5,954   0.032

Includes subjects from UPREST and UPDOSE (*n* = 24). Source of some immunofluorescence markers differed for UP50, resulting in changes in baseline values, so these healthy subjects were not included.

###### 

Summary of UFP exposure effects.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protocol              Adhesion molecules                                Lymphocyte subsets and activation        Leukocyte counts
  --------------------- ------------------------------------------------- ---------------------------------------- ---------------------------------------------
  UPREST (*n* = 12)     No convincing effects (see text)                  No effects                               No effects

  UPDOSE (*n* = 12)     Decreased monocyte CD54\                          Increased CD25^+^ T cells (females)      Decreased monocytes and basophils (females)
                        Decreased PMN CD49d (males)                                                                

  UP50 (*n* = 16)       Decreased monocyte CD18 and CD54 (males)          Increased CD25^+^ T cells                Decreased eosinophils

                        Decreased PMN CD18 and increased CD11a                                                     

  UPASTHMA (*n* = 16)   Decreased monocyte CD11b\                         Decreased CD4^+^ T cells and basophils   Decreased eosinophils
                        Decreased PMN CD54 and increased CD62L (males)\                                            
                        Decreased eosinophil CD11b                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------
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